| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G |
| 13 Nov 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Pyxis Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: |
| 06 Nov 2026 |
Form 4: Humphrey Rachel, Director
Granted 34,500 Stock Option (Right to Buy) |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Pyxis Oncology Reports Third Quarter 2026 Financial Results and Highlights Progress Toward Pivotal Development of Micvotabart Pelidotin (MICVO) |
| 03 Nov 2026 | SCHEDULE 13G/A |
| 21 Oct 2026 | DEF 14A |
| 09 Oct 2026 | PRE 14A |
| 09 Oct 2026 | SCHEDULE 13G/A |
| 09 Oct 2026 |
Form 4/A: GordonMD Global Investments Lp, 10% owner and 3 others
Acquired 7,172,000 Common Stock Purchase Warrant (Open Market Purchase) |
| 05 Oct 2026 | SCHEDULE 13G |
| 02 Oct 2026 |
Form 4: GordonMD Global Investments Lp, 10% owner and 3 others
Bought 5,517,000 shares · Acquired 7,546,766 Common Stock Purchase Warrant (Open Market Purchase) |
| 02 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Common Warrants to Purchase up to 49,310,352 Shares of Common Stock |
| 01 Oct 2026 | FORM 424B5 |
| 29 Sep 2026 | FORM 424B5 |
| 29 Sep 2026 | FORM 424B5 |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) |
Loading...